Synta Pharma offers positive ganetespib interim results, +15% premarket

|By:, SA News Editor

Synta Pharmaceuticals (SNTA+15% premarket after announcing "positive" Interim results from the ENCHANT-1 trial of ganetespib in metastatic breast cancer at a breast cancer symposium.

Early results demonstrated the drug is clinically active as a single-agent in both HER2+ and triple-negative metastatic breast cancers, SNTA says.